Monday, October 3, 2022


Biotechnology News Magazine

ECI Pharmaceuticals LLC Enters into Exclusive U.S. Distribution Agreement for Ibuprofen Prescription Strength Tablets and Folic Acid Prescription Strength Tablets

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

ECI Pharmaceuticals, LLC (ECI) today announced that it has entered into an exclusive U.S. distribution agreement with AiPing Pharmaceuticals, Inc. (AiPing) to manage the sales, marketing, and distribution of Ibuprofen 400 mg, 600 mg, 800 mg tablets, and Folic Acid 1 mg tablets.

According to IQVIA data for the 12 months ended December 2020, total U.S. generic sales of Ibuprofen tablets 400 mg, 600 mg, 800 mg was approximately $110 million. Generic Folic Acid tablets 1 mg were approximately $20 million for the same period. ECI plans to launch both Ibuprofen and Folic Acid under the ECI label.

“We are pleased to expand our sales, marketing, and distribution agreement with AiPing to include these additional products,” said Andrew Berk, Senior Director Business Development and Strategy for ECI. “AiPing has been a collaborator of ECI for several years on another ANDA product, and we look forward to our continued success in expanding our relationship with these highly valued and widely used generic pharmaceutical products.”

“We have chosen to expand our alliance with ECI because of our successful collaboration on another generic product,” commented Emma Li XU, CEO of AiPing “We are broadening our relationship with ECI because of their team’s ability to launch products swiftly and execute launch plans well. We will work closely with ECI to launch these products in the coming weeks.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine